Investigation of the human metabolism and disposition of the prolyl hydrolase inhibitor daprodustat using IV microtracer with Entero‐Test bile string
Abstract Daprodustat is an oral small molecule hypoxia‐inducible factor (HIF) prolyl hydroxylase inhibitor (PHI) approved in Japan and the United States for the treatment of anemia associated with chronic kidney disease. This phase 1, nonrandomized, 2‐period, crossover study in 6 healthy men charact...
Main Authors: | Guoying Tai, Fangming Xia, Cathy Chen, Adrian Pereira, Jill Pirhalla, Xiusheng Miao, Graeme Young, Claire Beaumont, Liangfu Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-12-01
|
Series: | Pharmacology Research & Perspectives |
Subjects: | |
Online Access: | https://doi.org/10.1002/prp2.1145 |
Similar Items
-
Successful treatment of low‐risk myelodysplastic syndrome‐related anemia in patients with chronic kidney disease with daprodustat: A report of two cases
by: Hiroyoshi Kunimoto, et al.
Published: (2024-12-01) -
Daprodustat: A potential game-changer in renal anemia therapy—A perspective
by: Muhammad Usman Haider, et al.
Published: (2023-08-01) -
Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis
by: Qiyan Zheng, et al.
Published: (2021-01-01) -
Daprodustat for anaemia in patients with heart failure and chronic kidney disease: A randomized controlled study
by: Takashi Iso, et al.
Published: (2022-12-01) -
The role and clinical implications of HIF-PHI daprodustat in dialysis-dependent and non-dialysis-dependent chronic kidney disease anemic patients: a general review
by: Yousuf Abdulkarim Waheed, et al.
Published: (2024-12-01)